[Skip to Navigation]
Sign In
Editorial
January 2016

Cancer Hallmark–Based Gene Sets and Personalized Medicine for Patients With Stage II Colon Cancer

Author Affiliations
  • 1Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania
  • 2NRG Oncology, Pittsburgh, Pennsylvania
  • 3Division of Hematology & Oncology, University of Florida, Gainesville
JAMA Oncol. 2016;2(1):23-24. doi:10.1001/jamaoncol.2015.3614

One of the most controversial areas of clinical oncology is the postoperative management of patients with stage II colon cancer. The promise of personalized medicine and tailored decision making has been taunting clinicians in this disease setting for the past decade. Multiple efforts to identify molecular signatures that provide an accurate and personalized assessment of the risk of relapse (ie, prognostic signatures) and an accurate and personalized assessment of the benefit from adjuvant chemotherapy (ie, predictive signatures) have been made, but this holy grail combination of personalized oncology has remained elusive.

Add or change institution
×